These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 35598686)

  • 1. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
    Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
    Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
    Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the dynamic changes in gut microbiota in patients with extremely severe burns by 16S ribosomal RNA high-throughput sequencing technology].
    Pan YY; Fan YF; Li JL; Cui SY; Huang N; Jin GY; Chen C; Zhang C
    Zhonghua Shao Shang Za Zhi; 2020 Dec; 36(12):1159-1166. PubMed ID: 33379852
    [No Abstract]   [Full Text] [Related]  

  • 7. The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial.
    Hui D; Liu L; Azami NLB; Song J; Huang Y; Xu W; Wu C; Xie D; Jiang Y; Bian Y; Sun M
    Front Endocrinol (Lausanne); 2022; 13():1107071. PubMed ID: 36743913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay of Lymphocytes with the Intestinal Microbiota in Children with Nonalcoholic Fatty Liver Disease.
    Liang T; Li D; Zunong J; Li M; Amaerjiang N; Xiao H; Khattab NM; Vermund SH; Hu Y
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
    Demir M; Lang S; Martin A; Farowski F; Wisplinghoff H; Vehreschild MJGT; Krawczyk M; Nowag A; Scholz CJ; Kretzschmar A; Roderburg C; Lammert F; Goeser T; Kasper P; Steffen HM
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1969-1977. PubMed ID: 32267559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.
    Jiang W; Wu N; Wang X; Chi Y; Zhang Y; Qiu X; Hu Y; Li J; Liu Y
    Sci Rep; 2015 Feb; 5():8096. PubMed ID: 25644696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic microbiome in healthy lean and obese humans.
    Suppli MP; Bagger JI; Lelouvier B; Broha A; Demant M; Kønig MJ; Strandberg C; Lund A; Vilsbøll T; Knop FK
    JHEP Rep; 2021 Aug; 3(4):100299. PubMed ID: 34169247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease.
    Wang B; Jiang X; Cao M; Ge J; Bao Q; Tang L; Chen Y; Li L
    Sci Rep; 2016 Aug; 6():32002. PubMed ID: 27550547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients.
    Li F; Sun G; Wang Z; Wu W; Guo H; Peng L; Wu L; Guo X; Yang Y
    Sci China Life Sci; 2018 Jul; 61(7):770-778. PubMed ID: 29948900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of 16S rRNA gut microbiota profiling of extremely low birth weight infants.
    Alcon-Giner C; Caim S; Mitra S; Ketskemety J; Wegmann U; Wain J; Belteki G; Clarke P; Hall LJ
    BMC Genomics; 2017 Nov; 18(1):841. PubMed ID: 29096601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 16. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
    Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
    Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease.
    Sookoian S; Salatino A; Castaño GO; Landa MS; Fijalkowky C; Garaycoechea M; Pirola CJ
    Gut; 2020 Aug; 69(8):1483-1491. PubMed ID: 31900291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CONSORT-Characteristics and metabolic phenotype of gut microbiota in NAFLD patients.
    Ge H; Wei W; Tang L; Tian Y; Zhu Y; Luo Y; Liu S
    Medicine (Baltimore); 2022 Jun; 101(25):e29347. PubMed ID: 35758365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.
    Lang S; Farowski F; Martin A; Wisplinghoff H; Vehreschild MJGT; Krawczyk M; Nowag A; Kretzschmar A; Scholz C; Kasper P; Roderburg C; Lammert F; Goeser T; Steffen HM; Demir M
    Sci Rep; 2020 Jun; 10(1):9385. PubMed ID: 32523101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.